Physician profile
John C Rhee
NPI 1457385197
$12,668.01
in general payments reported to CMS, 2019-2025
18 companies · $1,946 in 2025
The $1,946 reported for 2025 was more than what a typical Hematology & Oncology provider received nationally (typical 2025 total: $686).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,665 · 2020: $1,241 · 2021: $257 · 2022: $1,524 · 2023: $3,144 · 2024: $2,890 · 2025: $1,946.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Consulting Fee: $7,196 · Food and Beverage: $763 · Education: $21.00.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Consulting Fee | $7,195.50 |
| Food and Beverage | $763.31 |
| Education | $21.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals Lp | $6,804.21 | 2023-2025 | Imfinzi, Imjudo |
| Seagen INC. | $2,251.00 | 2020-2022 | |
| Dendreon Pharmaceuticals LLC | $1,635.22 | 2019 | |
| Daiichi Sankyo INC. | $525.00 | 2024 | Enhertu |
| E.R. Squibb & Sons, L.L.C. | $496.51 | 2021-2025 | Opdivo |
| Novocure Gmbh | $250.00 | 2022 | |
| Ipsen Biopharmaceuticals, INC | $191.59 | 2024 | Onivyde, Somatuline Depot |
| Eagle Pharmaceuticals, INC. | $148.80 | 2022 | |
| Celgene Corporation | $98.37 | 2019-2024 | Pomalyst |
| Mirati Therapeutics, INC. | $51.25 | 2023-2024 | Krazati |
| Exelixis INC. | $41.20 | 2021 | |
| Beone Medicines USA, INC. | $36.83 | 2025 | Brukinsa |
| Eisai INC. | $33.89 | 2025 | |
| Novartis Pharmaceuticals Corporation | $33.82 | 2024-2025 | |
| Lilly USA, LLC | $27.54 | 2023 | Retevmo, Verzenio |
Show all 18 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Array Biopharma INC | $17.83 | 2025 | Braftovi |
| Bayer Healthcare Pharmaceuticals INC. | $13.52 | 2023 | |
| Medtronic Vascular, INC. | $11.43 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw John Rhee listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.